Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab
- Veila Bio to receive $30M upfront licensing fee- additional payment on development and commercial milestones plus royalties on sales of product post-launch
- MTPC to get exclusive rights to develop and commercialize the product in Japan- South Korea- Taiwan- Singapore- Indonesia- Thailand- Malaysia- the Philippines and Vietnam
- Inebilizumab is an anti-CD19 mAb that binds to CD19 with high affinity and is currently under investigation for the treatment of neuromyelitis optica spectrum- disorder (NMOSD)
Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Twitter
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].